Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE clarithromycin trial in early COVID-19
2020-001882-36Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of clarithromycin in coronavirus disease 2019 (COVID-19) and viral pneumonia (2 arms), sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: Composite clinical endpoint at day 8. Started Apr 2020; status: completed.
02
Drugs
clarithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-001882-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001882-36.